Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1752W HIGH $7.08
Volume
161.17 K
Value Traded
2.97 M
Short % Float
3.64%
-11.83%Week
-9.2%1 Month
-13.76%3 Month
+96.52%6 Month
-90.68%5 Year
-88.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
256.89 M
EPS (TTM)
-0.92
P/E Ratio
-
Ent. Value
270.48 M
Total Shares
65.03 M
Float Shares
47.67 M
Insiders
26.71%
Institutions
49.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TMCI Catalyst Timeline
Dated clinical, regulatory and corporate events for Treace Medical Concepts, Inc.
Past FDA Catalysts and PDUFA Decisions
How TMCI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Treace Medical Concepts, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TMCI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Treace John T.Director, Officer (Chief Executive Officer), 10% Owner | Buy | 11,000 7,404,383 held | $4.34 | 08/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TMCI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0 % (-100 %) | 488.00 K | 199.39 K | -76.48% ( -648.28 K) |
TMCI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TMCI ranks across every disease it competes in
Competitive Position is a premium feature
See how TMCI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTMCI News
TMCI▲ +8.7%on this news
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
Treace Medical Concepts reported its second quarter 2026 financial results, revealing a revenue of $45.4 million, down from $47.4 million in 2025. The company experienced a net loss of $(15.9) million but reduced cash usage significantly. Treace is optimistic about future growth, raising its revenue guidance for the year.
Read more →TMCITreace Medical Concepts Reports First Quarter 2026 Financial Results
Treace Medical Concepts reported its first quarter 2026 financial results, showing a revenue decline to $47.2 million from $52.6 million in Q1 2025. The company experienced a net loss of $(18.0) million and an adjusted EBITDA loss of $(5.5) million. Despite these challenges, Treace initiated a market release of its new SuperBite™ system and expanded its patent portfolio. The company reaffirmed its full-year revenue guidance, anticipating continued case volume growth.
Read more →TMCI▼ -7.5%on this newsshared move
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Treace Medical Concepts reported its financial results for Q4 and full-year 2025, showing a 2% increase in revenue year-over-year but a net loss of $(59.0) million. The company reduced cash usage significantly and increased its active surgeon base. However, it anticipates a potential revenue decline in 2026 due to shifts in product demand and pricing.
Read more →TMCI▼ -11.4%on this news· ran to -30% by day 3
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Treace Medical Concepts, Inc. has reported its financial results for Q4 and the full year of 2025, showing a revenue increase of 2% compared to 2024. Despite the growth in revenue, the company experienced a net loss of $(59.0) million for the year, an increase from the previous year’s loss. The company also announced projected revenue guidance for 2026, suggesting a possible decline. Notably, Treace has reduced cash usage significantly and increased its active surgeon base, indicating a proactive approach to operational challenges.
Read more →TMCITreace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference
Treace Medical Concepts showcased new product innovations and positive interim clinical study data at the ACFAS Annual Scientific Conference. The company presented findings from the ALIGN3D™ and MTA3D™ studies, highlighting advancements in their Lapiplasty® procedures. These innovations aim to strengthen Treace's position in the bunion treatment market and improve surgical outcomes.
Read more →TMCITreace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
Treace Medical Concepts, Inc. has released preliminary unaudited revenue figures for Q4 and full-year 2025, indicating a 2% increase in annual revenue but a 9% decline in Q4 revenue compared to the previous year. The company added approximately 202 active surgeons, reaching a total of about 3,337, and noted growth in procedure volumes driven by new 3D bunion technologies. However, Treace acknowledges ongoing challenges related to economic conditions and consumer sentiment, and has not provided guidance for 2026 at this time.
Read more →TMCITreace Medical Secures Up to $175 Million in Debt Financing New 5-Year Agreement Provides Continued Financial Strength & Flexibility
Treace Medical Concepts, Inc. has announced a new five-year $175 million senior secured loan arrangement with SLR Capital Partners. This financing includes $60 million in immediate term loans and further availability up to $65 million, along with a $50 million revolving credit facility. The funds will be used to prepay existing loans, reinforcing Treace's financial position and providing liquidity for future growth in the bunion surgery market. CEO John T. Treace emphasized that this financing enhances the company's competitive position and helps advance its commercial strategies.
Read more →TMCITreace Medical Concepts Reports Third Quarter 2025 Financial Results
Treace Medical Concepts reported its financial results for Q3 2025, revealing an 11% increase in revenue, totaling $50.2 million. The company also noted a net loss of $(16.3) million, though adjusted EBITDA improved significantly. Treace expanded its product offerings and patent portfolio, but has revised its full-year revenue guidance downwards due to expected lower sales of its flagship products and prevailing market conditions. Macroeconomic challenges and shifts in patient preferences have influenced these outcomes.
Read more →TMCITreace Medical Concepts Reports Second Quarter 2025 Financial Results
Treace Medical Concepts, Inc. reported its second quarter 2025 financial results, achieving a revenue of $47.4 million, which is a 7% growth from the previous year. The net loss was reduced by 18%, and the company improved its adjusted EBITDA by 58%. Treace also announced the full market release of three new bunion technology systems, which adds to its existing portfolio. Overall, the financial outlook for 2025 remains optimistic, with a revenue guidance of $224 million to $230 million.
Read more →TMCITreace Medical Concepts Reports First Quarter 2025 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. reported its financial results for the first quarter of 2025, indicating a revenue increase of 3% year-over-year. The company improved its net loss by 15% and achieved a notable improvement in adjusted EBITDA. Treace also expanded its product portfolio with new bunion systems and presented positive clinical data at a recent conference. Looking forward, the company is reaffirming its revenue guidance of $224 million to $230 million for the full year 2025.
Read more →TMCITreace Announces Upcoming Board Chair Transition
Treace Medical Concepts, Inc. announced a leadership transition with John T. Treace appointed as Chairman of the Board, effective after the 2025 Annual Meeting. He will succeed James T. Treace, who is retiring after years of service. The board's decision signifies a strategic shift as they aim to enhance innovations in the bunion treatment market. John T. Treace's experience as CEO is expected to support the company's growth objectives going forward.
Read more →TMCI▼ -5.9%on this news
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported its financial results for Q4 and full-year 2024, showcasing a 10% revenue increase to $68.7 million for the fourth quarter and a 12% increase for the full year to $209.4 million. The company significantly improved its adjusted EBITDA by 322%, reaching $11.1 million in Q4. However, there was an increase in net loss for the year, indicating ongoing challenges. Looking ahead, Treace is optimistic with a revenue guidance for 2025 that expects a growth of 7% to 10% compared to 2024.
Read more →TMCI▲ +14.5%on this news
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue
Treace Medical Concepts, Inc. announced its preliminary, unaudited revenue results for the fourth quarter and full year of 2024. The company reported a revenue increase of approximately 10% in Q4 and a 12% increase for the full year compared to 2023, aligning with previous guidance. Treace also noted an addition of 280 active surgeons, marking a significant rise in its user base. The company is optimistic about entering 2025 with new product launches aimed at further penetrating the bunion market.
Read more →TMCI▲ +6.1%on this news· ran to +48% by day 3
Treace Medical Concepts Reports Third Quarter 2024 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. reported its financial results for the third quarter of 2024, revealing a revenue increase of 11% year-over-year to $45.1 million. The company noted an improved net loss of ($15.4) million, down from ($17.5) million in the prior year, alongside a significant reduction in adjusted EBITDA loss. Treace announced the launch of its Nanoplasty 3D procedure as its entry into the osteotomy market, with plans for further technological expansions. Despite rising operating expenses, Treace believes it has the financial strength to pursue strategic investments and growth initiatives.
Read more →TMCITreace Files Patent Infringement and Unfair Competition Suit to Protect Lapiplasty Bunion Technology
Treace Medical Concepts, Inc. has initiated a patent infringement and unfair competition lawsuit against Stryker Corporation and its subsidiary for allegedly infringing on nine patents related to their Lapiplasty 3D Bunion Correction technologies. This legal action, filed in the U.S. District Court for New Jersey, seeks damages and injunctive relief. Treace aims to protect its pioneering innovations and reassure investors of its commitment to intellectual property rights amidst growing competition. The company anticipates significant financial improvements in the coming years, projecting a 50% increase in Adjusted EBITDA in 2024 and breakeven by 2025.
Read more →TMCI▲ +5.2%on this news
Treace Medical Concepts Reports Second Quarter 2024 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. reported its financial results for the second quarter of 2024, demonstrating a revenue rise of 6% to $44.5 million compared to the same period in 2023. The gross margin stood at a notable 80.2%, although the company faced increasing operating expenses totaling $57.1 million. A significant net loss of $21.2 million was reported, indicating challenges in profitability, despite a positive outlook corroborated by continued product innovation and a reaffirmation of its full-year revenue guidance.
Read more →TMCITreace Medical Concepts Reports First Quarter 2024 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported its financial results for Q1 2024, showing a revenue increase of 21% year-over-year to $51.1 million. Despite this growth, the company faced a net loss of $18.7 million, which is higher than the previous year's loss. They also revised their revenue guidance for the full year downward, citing competition and market changes. The company continues to innovate with new technologies and aims to improve its adjusted EBITDA in the coming months.
Read more →TMCITreace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance PONTE VEDRA, Fla. –
Treace Medical Concepts reported substantial financial growth for Q4 and full-year 2023, with revenues rising by 25% in the fourth quarter and 32% for the full year. The company attributes this growth to an expanding customer base and increased utilization of its Lapiplasty procedure kits. Despite these gains, Treace also faced challenges with operating expenses and increased net losses. For 2024, Treace anticipates continued growth, expecting revenues between $220 million and $225 million.
Read more →TMCI▲ +6.6%on this news
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue Company to Present at J.P. Morgan Healthcare Conference on Tuesday
Treace Medical Concepts, Inc. has announced preliminary unaudited revenue results for Q4 and full-year 2023, highlighting significant growth in financial performance. The company reported a Q4 revenue of $61.8 million to $62.2 million, marking an increase of approximately 25% year-over-year. For the full year, revenue reached between $186.7 million and $187.1 million, exceeding prior guidance and reflecting a 32% growth compared to 2022. Additionally, Treace plans to provide financial guidance for 2024 during its upcoming earnings call on February 27, 2024.
Read more →About Treace Medical Concepts, Inc.
Headquarters100 PALMETTO PARK PLACE, PONTE VEDRA, FL, 32081
BIOPHARMAWATCH ELITE PLUS
Trade the next TMCI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime